Live Breaking News & Updates on Molecular Neuropharmacology

Stay updated with breaking news from Molecular neuropharmacology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Putting JAMA Psychiatry and MIA to the Genetic Test

We can assess whether Mad in America readers or JAMA Psychiatry readers are being provided with the most robust scientific literature. ....

United States , United Kingdom , Los Angeles , E Fuller Torrey , Kenneth Kendler , Allen Frances , Stephen Stahl , Nancy Andreasen , Ronald Reagan , Bill Clinton , Peter Simons , Carolyn Rabinowitz , Thomas Jobe , Louisa Putnam , Thomas Insel , Peter Tyrer , John Kane , Joanna Moncrieff , Jeffrey Lieberman , Nassir Ghaemi , William Carpenter , Tim Kendall , Peter Simon , Eric Nestler , Kermit Cole , Steven Hyman ,

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of ...

NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, ....

United States , New York , Mark Jacobson , Darren Opland , American Psychiatric Association , A Foundation For Clinical Neuroscience , Drug Administration , Axsome Therapeutics Inc , Corporate Communications , World Trade Center , National Comorbidity Survey Replication , Forward Treatment , Attention Deficit , Hyperactivity Using Solriamfetol , Symptom Report Scale , Attention Deficit Hyperactivity Disorder , Axsome Therapeutics , Psychiatric Association , Statistical Manual , Mental Disorders , American Psychiatric Publishing , Psychiatry Reports , Molecular Neuropharmacology , Clinical Neuroscience , Second Edition , Mcgraw Hill Professional ,

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

NEW YORK, July 07, 2023 Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced. ....

New York , United States , Mark Jacobson , Darren Opland , World Trade Center , A Foundation For Clinical Neuroscience , Axsome Therapeutics Inc , Corporate Communications , National Comorbidity Survey Replication , American Psychiatric Association , Drug Administration , Forward Treatment , Attention Deficit , Hyperactivity Using Solriamfetol , Symptom Report Scale , Attention Deficit Hyperactivity Disorder , Axsome Therapeutics , Psychiatric Association , Statistical Manual , Mental Disorders , American Psychiatric Publishing , Psychiatry Reports , Molecular Neuropharmacology , Clinical Neuroscience , Second Edition , Mcgraw Hill Professional ,

Molecular hydrogen reduces neuropathic pain: Study

Researchers show in animal models that hydrogen-enriched water (H2) reduces neuropathic pain symptoms and associated mental problems. ....

Olga Pol , Sant Pau , Institute Of Neurosciences , Sant Pau Biomedical Research Institute , Hospital De La Santa Creu , Sant Pau Research Institute , Molecular Neuropharmacology , Ews India ,

Study suggests molecular hydrogen for treatment of chronic pain

Researchers show in animal models that hydrogen-enriched water (H2) reduces neuropathic pain symptoms and associated mental problems. ....

Olga Pol , Sant Pau , Institute Of Neurosciences , Sant Pau Biomedical Research Institute , Hospital De La Santa Creu , Sant Pau Research Institute , Molecular Neuropharmacology , Ews India ,